Conference Programme

Registration

Welcome from One Nucleus

Tony Jones, CEO, One Nucleus

Keynote Address – Financial Markets and What to Expect Next

With the US seen as the key market for UK life science companies and international VCs contributing the majority of the essential growth investment for UK biotechs (US > 30% in 2023), what’s happening in the global money markets and what does that mean for Life Sciences?
Will Walker-Arnott, Charles Stanley, David Stubbs, Raymond James

Panel: Mansion or Maisonette?  

With the new UK Government continuing to back policies to enable Life Sciences to be a key driver of economic growth, including pension reforms, tech transfer support and R&D tax incentives, what is a realistic aspiration for the UK sector?
Moderator: Timothy H. Ehrlich, Gunderson Dettmer
Panellists: Eric Mayes, Endomag, Sarah Haywood, Advanced Oxford, David Stubbs, Raymond James, Tony Hickson, Cancer Research Horizons, George Freeman MP

How Can Collaborators Extract Maximal Value From Data?

Antima Gupta, Collaborative Drug Discovery

Coffee Break

Keynote Address: Winner & Losers 2024

Mike Ward, Clarivate

Panel: What Happens After the Deal is Signed?

Discussions about the art of dealmaking normally focus on the partner search, the courtship dance, negotiation, due diligence and finally the deal getting signed. Yet in many ways, that is just the start. How should the dealmaking parties interact post-deal to maximise the value creation going forward? 
Moderator: Rienk Pypstra, tranScrip
Panellists: Amanda Lehmann, Astex Therapeutics, Anji Miller, LifeArc, Louise Jopling, Babraham Research Campus, Jane Winter, Seuss Consulting, Rachel Bradley, Penningtons Manches Cooper

Fireside Chat: Being a Patient Champion

Collectively and as individuals, the attraction of working in the Life Sciences industry is grounded in the desire to improve patients’ lives. How do you address the challenges of enabling patients and R&D leaders to understand each other’s priorities?
Elin Haf Davies, Aparito, Elaine Warburton, OBE, Javelo

Lunch

Panel: Why My Technology Would Appear Cheap at Twice the Price?

Panel Sponsor:
Session MC: Ayokunmi Ajetunmobi, Pioneer Group
Valuation is one of the most debated elements of any deal or transaction. This panel will discuss
(i) how the innovator should create and defend their proposed valuation
(ii) how the investor or buyer assesses the innovator’s homework
(iii) how do you know when to sign or walk away?
Moderator – Michael O’Kane, CoolReach Logistics
Panellists: Michael Murray, Murray International Partners, Claire Thompson, Agility Life Science, Barbara Domayne-Hayman, Francis Crick Institute, Claire Brown, Oxford Science Enterprises, Ayokunmi Ajetunmobi, Pioneer Group

Keynote Address: Introducing Disruptive Technologies: Lessons from a Passionate Entrepreneur

Elin Haf Davies, Aparito

Panel: Watch This Space!

With the pace of change increasing, sector commentators will discuss what they are most looking forward to writing about in the coming year.
Moderator: Femida Gwadry-Sridhar, Pulse Infoframe
Panellists: Megan Thomas, Drug Discovery World, Victoria English, MedNous, Lisa Melton, Nature Biotechnology

Coffee Break

Fireside Chat: Will the Political Landscape Be Good for Life Sciences?

David Rosenberg, Indiana Secretary of Commerce, Ramon Kaur, Director of Public Affairs, EY

Panel: Biology and Technology – Where Do You Fit and Who Does it Matter To?

Panel Sponsor: reserved
With the explosion of new terminology to describe the science of living things, such as Biotech, TechBio, Deep Biotech, Agri-Tech and HealthTech this panel will discuss where companies find their sense of identity when developing their value proposition.
Moderator: Tbc, Bruntwood SciTech
Panellists: Belinda Clarke, Agri-TechE, Catherine Stace, Kuano, Alicia Showering, BugBiome, Abigail Martin, ImmuONE

Fireside Chat – How does the UK plc CV Look to a Leading Bioentrepreneur?

Renos Savva, Discovery Park, Nara Daubeney, Phaim

Panel: Inside the Mind of a Life Science Investor

Panel Sponsor:
How much of investment decision-making is an art and how much is science? This panel of investment leaders will discuss their approach to selecting the right deals.
Moderator: Phil Masterson, Cancer Research Horizons
Panellists: Anne Horgan, Cambridge Innovation Capital, Kerstin Papenfuss, Deep Science Ventures, Ingrid Teigland Akay, Hadean Ventures, Zizi Imatorbhebhe, Bios Health Group, Jonathan Tobin, Brandon Capital/Cancer Research Horizons

Closing Remarks

Tony Jones, One Nucleus

Genesis – RESI London Drinks Reception

Close